Skip to main content
. 2016 Apr 20;7(22):33081–33095. doi: 10.18632/oncotarget.8859

Figure 1. Tumorigenic capacities of BALB-neuT Disseminated Tumor Cells (DTC).

Figure 1

A. Representative images of BM cells from BALB-neuT mice stained for Her2/neu oncogene (HER2) and Cytokeratin 8-18 (CK 8-18). CK8-18 positive cells are shown in green, HER2-positive cells in red and HER2/CK8-18 double-positive cells in yellow; nuclei are stained in blue. In the merge panel: 1, HER2-positive cells; 2, CK8-18 positive cell; 3, HER2/CK8-18 double-positive cell. Scale Bar, 20 μm. B. Growth curves of DTC tumors generated from the injection of late DTC from BALB-neuT BM pools. Tumor volumes were plotted as a function of time (weeks) after injection. C. Immunohistochemical analysis of HER2 expression in parental mammary tumor and tumors generated from the s.c. injection into NSG mice of BALB-neuT parental mammary tumor cells (mammary tumor, upper panels) and BALB-neuT BM cells (DTC tumor, lower panels). Light microscopy images were taken at 10x magnification (scale bar 200 μm) and 40x (scale bar 50 μm).